Irving-Based Biotech Joins Rare Disease Company Coalition to Support Innovation in Life Science

Rare is not that rare, says the RDCC. One in ten people lives with a rare disease, and the new coalition will unify life science companies dedicated to developing treatments. The goal? To inform policymakers of the unique challenges in the space.

Signature Biologics joins Dallas-based Taysha as a member of the RDCC.

Signature Biologics President and COO Chloe Bailey

Irving-headquartered Signature Biologics, a regenerative medicine company, has joined the ranks of the Rare Disease Company Coalition.

The RDCC, formed in May 2021, aims to be a unified voice of life science companies committed to discovering, developing, and delivering rare disease treatments

Signature Biologics, which is currently pursuing several pre-clinical products aimed to provide new solutions to patients with rare diseases, manufactures perinatal-derived products that could improve the body’s natural healing processes. The company recently announced expanded operations with a new 36,000-square-foot manufacturing and R&D headquarters in Irving.

“Our focus on bringing solutions to unmet clinical needs targets an array of rare diseases” said Chloe Bailey, president and COO at Signature Biologics, in a statement. “We’re extremely happy to share our voice with the Rare Disease Company Coalition to ensure navigation of the unique challenges in this space to bring innovations to these patients.”

According to Signature Biologics, it’s one of three life science companies in Texas that have been accepted into the national coalition. The biotech joins Dallas-based Taysha Gene Therapies and Austin-based Aeglea BioTherapeutics in the RDCC’s inaugural year.

The three Texas companies are among 18 on the RDCC roster to date. 

Rare diseases are not that rare

Betsy Ricketts, chair of the RDCC, says the coalition applauds the trio’s commitment to developing rare disease treatments through ongoing research and development, while often taking on “significant risk and uncertainty.” 

The RDCC wants to help inform policymakers on the need to develop treatments for rare conditions that actually aren’t so rare: One in 10 Americans are living with rare disease and have “extraordinarily high unmet needs,” according to the group. In addition, 93% of rare diseases have no FDA-approved treatment. 

Special challenges for continued progress

Biotech companies developing treatments for rare disease patients face multiple challenges, from clinical trial enrollment to proving meaningful endpoints due the smaller population sizes and “the more limited knowledge known about the disease progression,” per the RDCC.

Those challenges add up to a comparatively higher percentage of operating expenses that’s dedicated to research and development at these companies, the organization says. Last year, the coalition’s members invested more than $4.1 billion in research and development— an amount that represents more than half of their annual operating budgets on average.

“The sustained growth of the coalition is reflective of the need for ongoing education and engagement with policymakers on the importance of well-informed policy that can support continued progress for developing treatments for people with rare diseases,” Ricketts said in a statement.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

  • The City of Irving has won silver certification from Bloomberg Philanthropies' What Works Cities—the national standard of well-managed cities recognizing the most effective use of data to inform policy and funding decisions. The honor comes in a year that's tested the mettle of municipalities nationwide. Since 2018, 40 cities have achieved the certification. This year 16 new cities were recognized, including gold-winning Austin and silver-winning San Antonio. “During the pandemic, using data to inform decision-making was more important than ever for cities," said Michael Bloomberg in a statement. “By putting data at the center of their COVID-19 response efforts, these cities saved lives and…

  • Following the news last week that Brightstar was rebranding to Likewize, the company is now investing in a 275,000-square-foot automated facility in Flower Mound to serve as a global supply chain center of excellence that enhances the customer experience.

  • Authentix is adding to its portfolio of digital security technologies with Strategic IP Information Pte Ltd (SIPI), one of Asia's leaders in online brand and content rights protection. It's a big move in a burgeoning industry—one that is expected to grow by $58 billion until 2024—and on target with the local company's growth plan to integrate both online investigation and copyright protection services.

  • CompTIA Apprenticeships for Tech, funded by the U.S. Department of Labor, assists employers in upskilling and reskilling workers while creating a more diverse tech talent pipeline. Here's how companies, individuals, and educators can get involved.

  • There, Signature Biologics will manufacture perinatal-derived products that improve the body's natural healing processes in wound, musculoskeletal, and pain management applications.